BCL2L1 and gastric adenocarcinoma: Shan et al. reported α-MG (7 μg/mL) treatment markedly suppressed human gastric adenocarcinoma cells via the constitutive Stat3 protein activation, and Stat3-regulated Bcl-xL and Mcl-1 protein levels [25].